Weill Cornell

New York, NY

Sorting 9 by

Accepting patients

QUINTESSENTIAL-2

Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

DREAMM-10

Phase 3 Clinical Trial Comparing the Safety and Efficacy of Belantamab Mafodotin, Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplant
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

MonumenTAL-6

64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
  • Bispecific Antibody
  • GPRC5D
  • CD3
  • Randomization
  • Phase 3

Accepting patients

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3
  • Has results

Accepting patients

Sonrotoclax (BGB-11417)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

Linvoseltamab

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

Etentamig for Newly Diagnosed Patients

Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
  • Bispecific Antibody
  • CD3
  • BCMA
  • Randomization
  • Phase 2/3

Accepting patients

Etentamig (ABBV-383)

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1/2

Accepting patients

IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
  • Natural Killer Cells (Allogeneic)
  • Phase 1/2
2 hidden based on your filters.Show All